Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels

被引:41
作者
Carvalho, LJM
Oliveira, SG
Theisen, M
Alves, FA
Andrade, MCR
Zanini, GM
Brígido, MCO
Oeuvray, C
Póvoa, MM
Muniz, JAPC
Druilhe, P
Daniel-Ribeiro, CT
机构
[1] Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Malaria Res Lab, BR-21045900 Rio De Janeiro, Brazil
[2] Inst Evandro Chagas, Belem, Para, Brazil
[3] Statens Serum Inst, DK-2300 Copenhagen, Denmark
[4] Natl Primate Ctr, Belem, Para, Brazil
[5] Fiocruz MS, CECAL, Dept Primatol, BR-21045900 Rio De Janeiro, Brazil
[6] Inst Pasteur, Paris, France
关键词
D O I
10.1111/j.0300-9475.2004.01409.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immunogenicity and protective efficacy of various antigen-adjuvant formulations derived either from the merozoite-surface protein-3 (MSP-3) or the glutamate-rich protein (GLURP) of Plasmodium falciparum were evaluated in Saimiri sciureus monkeys. These proteins were selected for immunogenicity studies based primarily on their capacity of inducing an antibody-dependent cellular inhibition effect on parasite growth. Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 29 条
  • [1] [Anonymous], 1988, B WORLD HEALTH ORGAN, V66, P719
  • [2] ARIGA S, 1978, J MED PRIMATOL, V7, P129
  • [3] Human malaria in immunocompromised mice:: An in vivo model to study defense mechanisms against Plasmodium falciparum
    Badell, E
    Oeuvray, C
    Moreno, A
    Soe, S
    van Rooijen, N
    Bouzidi, A
    Druilhe, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) : 1653 - 1659
  • [4] ANTIBODIES THAT PROTECT HUMANS AGAINST PLASMODIUM-FALCIPARUM BLOOD STAGES DO NOT ON THEIR OWN INHIBIT PARASITE GROWTH AND INVASION INVITRO, BUT ACT IN COOPERATION WITH MONOCYTES
    BOUHAROUNTAYOUN, H
    ATTANATH, P
    SABCHAREON, A
    CHONGSUPHAJAISIDDHI, T
    DRUILHE, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) : 1633 - 1641
  • [5] Carvalho LJD, 2003, MEM I OSWALDO CRUZ, V98, P679, DOI 10.1590/S0074-02762003000500016
  • [6] Malaria vaccine: Candidate antigens, mechanisms, constraints and prospects
    Carvalho, LJM
    Daniel-Ribeiro, CT
    Goto, H
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 56 (04) : 327 - 343
  • [7] GAMMA-GLOBULIN AND ACQUIRED IMMUNITY TO HUMAN MALARIA
    COHEN, S
    CARRINGTON, S
    MCGREGOR, IA
    [J]. NATURE, 1961, 192 (480) : 733 - &
  • [8] Plasmodium falciparumin the squirrel monkey (Saimiri sciureus):: infection of non-splenectomised animals as a model for exploring clinical manifestations of malaria
    Contamin, H
    Behr, C
    Mercereau-Puijalon, O
    Michel, JC
    [J]. MICROBES AND INFECTION, 2000, 2 (08) : 945 - 954
  • [9] Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria
    Dodoo, D
    Theisen, M
    Kurtzhals, JAL
    Akanmori, BD
    Koram, KA
    Jepsen, S
    Nkrumah, FK
    Theander, TG
    Hviid, L
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) : 1202 - 1205
  • [10] Druilhe P, 1997, ANN TROP MED PARASIT, V91, pS37, DOI 10.1080/00034989761292